news Research identifies novel unconventional type of immune cell capable of fighting viral infections 4 May 2018 | By Drug Target Review Research led by the University of Birmingham has identified a novel unconventional type of immune cell capable of fighting viral infections.
news T cell populations in CLL patients indicate potential success of CAR-T cell therapy 3 May 2018 | By Drug Target Review Researchers have discovered the reason why some patients with advanced chronic lymphocytic leukaemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy...
article Taking the brakes off the immune system: modelling effects in non-clinical safety studies 2 May 2018 | By Greg Bannish - Vice President Biopharmaceutical Development Envigo This article focuses on how the immune system functions, the challenges that it presents to drug development and why there are such concerns around safety that need to be investigated in pre-clinical studies. Moreover, it covers the role of checkpoint inhibitors as an attractive target for cancer immunotherapy.
news Researchers uncover origin of virus-fighting plasma B cells 19 April 2018 | By Drug Target Review A group of researchers have discovered an important mechanism that governs how B cells are chosen to become plasma cells...
news Study develops compound that activates tumour-fighting iNKT cells 6 April 2018 | By Drug Target Review Researchers have discovered a significant new compound that helps to mobilise a type of T cell – invariant natural killer T (iNKT) cells – in the fight against disease.
article Lymphocytes armed to kill: how customised cell engineering advances immunotherapy 4 April 2018 | By Drug Target Review The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology...
article High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform 19 March 2018 | By IntelliCyt Corporation This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
news Extracellular vesicles could be personalised drug delivery vehicles 15 March 2018 | By Drug Target Review Researchers developed an approach and platform to create large amounts of fillable and targeted nanovesicles to deliver drugs to tumours in mice...
news Preventing exhaustion in immune cells boosts immunotherapy in mice 7 March 2018 | By Drug Target Review Research shows that preventing or reversing ‘T-cell exhaustion’ with targeted therapies could enhance the effects of immunotherapy.
news Study suggests PD-1 inhibitors against aggressive pediatric brain cancer subtype 31 January 2018 | By Drug Target Review A study has laid the groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.
news Gimap5 gene mutations found to trigger immune diseases 30 January 2018 | By Dr Zara Kassam (Drug Target Review) Scientists discovered how a gene mutation affects T cell function to promote immune disorders...
news Genomic tools reveal diverse behaviour in immune cells 22 January 2018 | By Drug Target Review New research from La Jolla Institute for Allergy and Immunology using single-cell transcriptome analysis yields greater understanding of the human immune system.
news APC-mimetic scaffolds could facilitate more effective precision immunotherapies 16 January 2018 | By Dr Zara Kassam (Drug Target Review) Amplifying patient-specific T cells outside the body could increase the efficiency of cancer immunotherapies...
news Immune cells dictate tumour progression 15 January 2018 | By Dr Zara Kassam (Drug Target Review) Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
news Researchers use AI technology to chart immune cell receptor 10 January 2018 | By Drug Target Review Johns Hopkins scientists have used a form of artificial intelligence to create a map that compares types of cellular receptors, the chemical ‘antennas’ on the surface of immune system T-cells.
